Immunoprevention of human papillomavirus-associated malignancies
- PMID: 25488410
- PMCID: PMC4315720
- DOI: 10.1158/1940-6207.CAPR-14-0311
Immunoprevention of human papillomavirus-associated malignancies
Abstract
Persistent infection by one of 15 high-risk human papillomavirus (hrHPV) types is a necessary but not sufficient cause of 5% of all human cancers. This provides a remarkable opportunity for cancer prevention via immunization. Since Harald zur Hausen's pioneering identification of hrHPV types 16 and 18, found in approximately 50% and 20% of cervical cancers, respectively, two prophylactic HPV vaccines containing virus-like particles (VLP) of each genotype have been widely licensed. These vaccines are beginning to affect infection and HPV-associated neoplasia rates after immunization campaigns in adolescents. Here, we review recent progress and opportunities to better prevent HPV-associated cancers, including broadening immune protection to cover all hrHPV types, reducing the cost of HPV vaccines especially for developing countries that have the highest rates of cervical cancer, and immune-based treatment of established HPV infections. Screening based upon George Papanicolaou's cervical cytology testing, and more recently detection of hrHPV DNA/RNA, followed by ablative treatment of high-grade cervical intraepithelial neoplasia (CIN2/3) have substantially reduced cervical cancer rates, and we examine their interplay with immune-based modalities for the prevention and eventual elimination of cervical cancer and other HPV-related malignancies.
©2014 American Association for Cancer Research.
Figures


Similar articles
-
Cervical cancer: screening and prevention.Asian Pac J Cancer Prev. 2006 Oct-Dec;7(4):683-6. Asian Pac J Cancer Prev. 2006. PMID: 17250453 Review.
-
Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.J Clin Virol. 2016 Mar;76 Suppl 1:S29-S39. doi: 10.1016/j.jcv.2015.11.021. Epub 2015 Nov 19. J Clin Virol. 2016. PMID: 26643051
-
Human papillomavirus vaccines versus cervical cancer screening.Clin Oncol (R Coll Radiol). 2008 Aug;20(6):388-94. doi: 10.1016/j.clon.2008.04.006. Epub 2008 Jun 5. Clin Oncol (R Coll Radiol). 2008. PMID: 18538554 Review.
-
[Cervical cancer prevention: the impact of HPV vaccination].Gynecol Obstet Fertil. 2006 Mar;34(3):189-201. doi: 10.1016/j.gyobfe.2006.01.036. Epub 2006 Mar 10. Gynecol Obstet Fertil. 2006. PMID: 16529969 Review. French.
-
The efficacy of human papillomavirus prophylactic vaccination after conization in preventing cervical intraepithelial neoplasia recurrence: A prospective observational study in China.Eur J Obstet Gynecol Reprod Biol. 2023 Jul;286:10-15. doi: 10.1016/j.ejogrb.2023.04.014. Epub 2023 Apr 19. Eur J Obstet Gynecol Reprod Biol. 2023. PMID: 37159990
Cited by
-
Mouse papillomavirus infections spread to cutaneous sites with progression to malignancy.J Gen Virol. 2017 Oct;98(10):2520-2529. doi: 10.1099/jgv.0.000926. J Gen Virol. 2017. PMID: 28942760 Free PMC article.
-
Immunologic Control of Mus musculus Papillomavirus Type 1.PLoS Pathog. 2015 Oct 23;11(10):e1005243. doi: 10.1371/journal.ppat.1005243. eCollection 2015 Oct. PLoS Pathog. 2015. PMID: 26495972 Free PMC article.
-
Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded.Infect Agent Cancer. 2025 Mar 10;20(1):16. doi: 10.1186/s13027-025-00643-5. Infect Agent Cancer. 2025. PMID: 40059217 Free PMC article. Review.
-
Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease.Cell Biosci. 2016 Feb 25;6:16. doi: 10.1186/s13578-016-0080-z. eCollection 2016. Cell Biosci. 2016. PMID: 26918115 Free PMC article.
-
Human papillomavirus and gastrointestinal cancer: A review.World J Gastroenterol. 2016 Sep 7;22(33):7415-30. doi: 10.3748/wjg.v22.i33.7415. World J Gastroenterol. 2016. PMID: 27672265 Free PMC article. Review.
References
-
- Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133–45. - PubMed
-
- D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. The New England journal of medicine. 2007;356:1944–56. - PubMed
-
- de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. The lancet oncology. 2012;13:607–15. - PubMed
-
- CDC Disease Burden from Viral Hepatitis A, B, and C in the United States. Last Accessed 5th May 2014]. Available from: http://www.cdc.gov/hepatitis/HBV/StatisticsHBV.htm.
-
- Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports / Centers for Disease Control. 2006;55:1–33. quiz CE1-4. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical